SMEE Lithography R&D Shift: Divesting Manufacturing to Accelerate Chip Self-Sufficiency
China's SMEE divests manufacturing assets to focus on its SMEE lithography R&D shift. The move aims to close the tech gap with ASML and bolster chip self-sufficiency.
China's leading light in the semiconductor race isn't standing still. Shanghai Micro Electronics Equipment (SMEE), the nation's best bet to challenge Dutch giant ASML, just reshuffled its business to double down on research. By divesting a manufacturing arm, the firm's signaling a pivot from production to high-end innovation.
SMEE Lithography R&D Shift: Shedding Weight for Speed
According to the corporate database Qichacha, SMEE transferred 100% of its subsidiary, Shanghai Weiyao Industrial, to AMIES Technology. The deal, valued at approximately 228.5 million yuan, moves manufacturing assets off the balance sheet so the company can sharpen its focus on Beijing's push for advanced chipmaking tech.
Closing the Gap with ASML
Industry insiders suggest this isn't just a simple sale. It's a calculated retreat to the lab. SMEE's primary mission is to break the Western monopoly on lithography—the process of etching circuits onto silicon. As global export controls tighten, developing domestic alternatives to ASML's systems has become a top-tier national security priority for China.
This content is AI-generated based on source articles. While we strive for accuracy, errors may occur. We recommend verifying with the original source.
Related Articles
A China-led team has developed the world's first mini-womb on a chip, replicating human embryo implantation to solve infertility mysteries and improve IVF success.
Grab a deal with the Solawave BOGO sale 2026. Get two viral LED wands or masks for the price of one. Check specs and pricing now.
Explore the top humanoid robots from CES 2026, including Dyna Robotics' laundry folder and EngineAI's boxers, as they move toward real-world deployment.
The SandboxAQ Jack Hidary lawsuit 2026 reveals allegations of financial misconduct and misuse of funds. PRISM examines the battle within the $5.75B startup.